© 1997 American Heart Association, Inc.
Articles |
HDL Deficiency in Genetically Engineered Mice Requires Elevated LDL to Accelerate Atherogenesis
From the Human Genome Center, Life Science Division, Lawrence Berkeley Laboratory, Berkeley, Calif.
Correspondence to Edward M. Rubin, Human Genome Center, Lawrence Berkeley Laboratory, 1 Cyclotron Rd, Berkeley, CA 94720. E-mail emrubin{at}lbl.gov
Abstract In humans, a low HDL concentration is one of the strongest indicators of increased risk for coronary heart disease. Apolipoprotein A-I (apo A-I) synthetic defects result in extremely low HDL levels and are frequently although not invariably associated with premature atherosclerosis. To investigate atherosclerosis susceptibility associated with HDL deficiency alone and in combination with other risk factors, such as high levels of LDL, we have quantified diet-induced atherogenesis in a series of genetically engineered mice, including mice with low HDL levels due to targeted disruption of both apo A-I alleles (AI KO mice), mice with high LDL levels due to expression of a human apolipoprotein B transgene (Btg mice), and mice with combined high LDL and low HDL levels due to the presence of the human apo B transgene and apo A-I knockout alleles, respectively (AI KO/Btg mice). After exposure to an atherogenic diet, AI KO and control mice had negligible lesions. All mice expressing the apo B transgene developed extensive lesions, but AI KO/Btg mice developed significantly larger lesions than Btg mice: 56, 260±4630 µm2 for AI KO/Btg (n=27) versus 38, 120±3350 µm2 for Btg mice (n=19) (P<.02). Results of this study, consistent with several human epidemiological studies, indicate that HDL deficiency in the mouse does not by itself lead to the development of atherosclerosis but does increase atherosclerosis susceptibility when accompanied by other risk factors, in this case elevated LDL.
Key Words: apolipoprotein A-I • apolipoprotein B • atherosclerosis • genetics • lipoproteins • transgenic mice
This article has been cited by other articles:
 |
|
 |
|
  S. Acin, M. A. Navarro, J. M. Arbones-Mainar, N. Guillen, A. J. Sarria, R. Carnicer, J. C. Surra, I. Orman, J. C. Segovia, R. d. l. Torre, et al. Hydroxytyrosol Administration Enhances Atherosclerotic Lesion Development in Apo E Deficient Mice J. Biochem., September 1, 2006; 140(3): 383 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Y. Han, T. Chiba, J. S. Campbell, N. Fausto, M. Chaisson, G. Orasanu, J. Plutzky, and A. Chait Reciprocal and Coordinate Regulation of Serum Amyloid A Versus Apolipoprotein A-I and Paraoxonase-1 by Inflammation in Murine Hepatocytes Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1806 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Moore, M.-a. Kawashiri, K. Kitajima, A. Secreto, J. S. Millar, D. Pratico, and D. J. Rader Apolipoprotein A-I Deficiency Results in Markedly Increased Atherosclerosis in Mice Lacking the LDL Receptor Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1914 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zabalawi, S. Bhat, T. Loughlin, M. J. Thomas, E. Alexander, M. Cline, B. Bullock, M. Willingham, and M. G. Sorci-Thomas Induction of Fatal Inflammation in LDL Receptor and ApoA-I Double-Knockout Mice Fed Dietary Fat and Cholesterol Am. J. Pathol., September 1, 2003; 163(3): 1201 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. van Haperen, A. van Tol, T. van Gent, L. Scheek, P. Visser, A. van der Kamp, F. Grosveld, and R. de Crom Increased Risk of Atherosclerosis by Elevated Plasma Levels of Phospholipid Transfer Protein J. Biol. Chem., December 6, 2002; 277(50): 48938 - 48943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Furbee Jr., J. K. Sawyer, and J. S. Parks Lecithin:Cholesterol Acyltransferase Deficiency Increases Atherosclerosis in the Low Density Lipoprotein Receptor and Apolipoprotein E Knockout Mice J. Biol. Chem., January 25, 2002; 277(5): 3511 - 3519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Martin-Campos, J. Julve, J. C. Escola, J. Ordonez-Llanos, J. Gomez, J. Binimelis, F. Gonzalez-Sastre, and F. Blanco-Vaca ApoA-IMALLORCA impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia J. Lipid Res., January 1, 2002; 43(1): 115 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Shah, S. Kaul, J. Nilsson, and B. Cercek Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I Circulation, November 6, 2001; 104(19): 2376 - 2383. [Full Text] [PDF]
|
|
|
|
|
|
M. G. Sorci-Thomas, M. Thomas, L. Curtiss, and M. Landrum Single Repeat Deletion in ApoA-I Blocks Cholesterol Esterification and Results in Rapid Catabolism of Delta 6 and Wild-type ApoA-I in Transgenic Mice J. Biol. Chem., April 14, 2000; 275(16): 12156 - 12163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Kozarsky, M. H. Donahee, J. M. Glick, M. Krieger, and D. J. Rader Gene Transfer and Hepatic Overexpression of the HDL Receptor SR-BI Reduces Atherosclerosis in the Cholesterol-Fed LDL Receptor-Deficient Mouse Arterioscler. Thromb. Vasc. Biol., March 1, 2000; 20(3): 721 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Calleja, M. A. Paris, A. Paul, E. Vilella, J. Joven, A. Jimenez, G. Beltran, M. Uceda, N. Maeda, and J. Osada Low-Cholesterol and High-Fat Diets Reduce Atherosclerotic Lesion Development in ApoE-Knockout Mice Arterioscler. Thromb. Vasc. Biol., October 1, 1999; 19(10): 2368 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Plump and M. W. Ketterer Cardiovascular Medicine at the Turn of the Millennium N. Engl. J. Med., March 26, 1998; 338(13): 919 - 920. [Full Text]
|
|
|
|
|
|
H.-h. Li, D. S. Lyles, M. J. Thomas, W. Pan, and M. G. Sorci-Thomas Structural Determination of Lipid-bound ApoA-I Using Fluorescence Resonance Energy Transfer J. Biol. Chem., November 17, 2000; 275(47): 37048 - 37054. [Abstract] [Full Text] [PDF]
|
|